Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long‐Term Follow‐Up: Results From the NODE‐302 Study
التفاصيل البيبلوغرافية
العنوان:
Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long‐Term Follow‐Up: Results From the NODE‐302 Study
Background Self‐administration of investigational intranasal L‐type calcium channel blocker etripamil during paroxysmal supraventricular tachycardia (PSVT) appeared safe and well‐tolerated in the phase 3 NODE‐301 (Multi‐Centre, Randomized, Double‐Blind, Placebo‐Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia) trial of adults with sustained atrioventricular nodal‐dependent PSVT. The NODE‐302 open‐label extension further characterized etripamil safety and efficacy. Methods and Results Eligible patients were monitored via self‐applied cardiac monitoring system for 5 hours after etripamil self‐administration. The primary end point was time‐to‐conversion of positively adjudicated PSVT to sinus rhythm after etripamil treatment. Probability of conversion to sinus rhythm was reported via Kaplan‐Meier plot. Adverse events were based on self‐reported symptoms and clinical evaluations. Among 169 patients enrolled, 105 self‐administered etripamil ≥1 time for perceived PSVT (median [range], 232 [8–584] days' follow‐up). Probability of conversion within 30 minutes of etripamil was 60.2% (median time to conversion, 15.5 minutes) among 188 PSVT episodes (92 patients) positively adjudicated as atrioventricular nodal dependent by independent ECG analysis. Among 40 patients who self‐treated 2 episodes, 75% had a significantly consistent response by 30 minutes; 9 did not convert on either episode, and 21 converted on both episodes (χ2=8.09; P=0.0045). Forty‐five of 105 patients (42.9%) had ≥1 treatment‐emergent adverse event, generally transient and mild‐to‐moderate, including nasal congestion (14.3%), nasal discomfort (14.3%), or rhinorrhea (12.4%). No serious cardiac safety events were observed within 24 hours of etripamil. Conclusions In this extension study, investigational etripamil nasal spray was well tolerated for self‐treating recurrent episodes of PSVT without medical supervision. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03635996.